Today's Top Performers In Drugs

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 10 points (-0.1%) at 16,415 as of Thursday, April 17, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,581 issues advancing vs. 1,369 declining with 186 unchanged.

The Drugs industry currently sits down 0.1% versus the S&P 500, which is unchanged. Top gainers within the industry include Incyte ( INCY), up 2.3%, and Sanofi ( SNY), up 0.7%. A company within the industry that fell today was Shire ( SHPG), up 0.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Teva Pharmaceutical Industries ( TEVA) is one of the companies pushing the Drugs industry higher today. As of noon trading, Teva Pharmaceutical Industries is up $0.65 (1.3%) to $50.56 on light volume. Thus far, 2.3 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 7.3 million shares. The stock has ranged in price between $50.04-$50.64 after having opened the day at $50.14 as compared to the previous trading day's close of $49.91.

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Teva Pharmaceutical Industries has a market cap of $47.0 billion and is part of the health care sector. Shares are up 24.5% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts who rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 11 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Teva Pharmaceutical Industries Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Allergan ( AGN) is up $1.55 (1.2%) to $133.01 on heavy volume. Thus far, 3.1 million shares of Allergan exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $129.20-$134.41 after having opened the day at $130.38 as compared to the previous trading day's close of $131.46.

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $38.2 billion and is part of the health care sector. Shares are up 18.4% year-to-date as of the close of trading on Wednesday. Currently there are 9 analysts who rate Allergan a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Allergan Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is up $0.78 (1.1%) to $70.06 on average volume. Thus far, 8.7 million shares of Gilead exchanged hands as compared to its average daily volume of 15.7 million shares. The stock has ranged in price between $69.09-$70.54 after having opened the day at $69.37 as compared to the previous trading day's close of $69.28.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $104.8 billion and is part of the health care sector. Shares are down 7.8% year-to-date as of the close of trading on Wednesday. Currently there are 18 analysts who rate Gilead a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Gilead Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%